HomeAI · summaries
Storia in 3 fonti
Subcutaneous Leqembi approved for initiation; long-term stability with treatment indicated
The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according to a press release from the administration. Previously, patients had to begin treatment with an intravenous dose. Researchers conducting a real-world study, presented at the Alzheimer’s Association International Conference, found that most patients remained stable over an
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- ·
economictimes.indiatimes.com
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving…
- ·
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world…
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- ·
healio.com
Subcutaneous Leqembi approved for initiation; long-term stability with treatment indicated
The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according to a press release from the administration.…